Out-of-pocket costs of HAART limit HIV treatment responses in Botswana's private sector
2006; Lippincott Williams & Wilkins; Volume: 20; Issue: 9 Linguagem: Inglês
10.1097/01.aids.0000232245.36039.2b
ISSN1473-5571
AutoresGregory P. Bisson, Ian Frank, Robert Gross, Vincent Lo Re, Jordan B. Strom, Xingmei Wang, Mpho Mogorosi, Tendani Gaolathe, Ndwapi Ndwapi, Harvey M. Friedman, Brian L. Strom, Diana Dickinson,
Tópico(s)HIV/AIDS drug development and treatment
ResumoA large number of HIV-infected patients in sub-Saharan Africa pay out-of-pocket for HAART. This analysis from Botswana indicates that higher median out-of-pocket regimen costs to patients for the initial 30 days of HAART are associated with failure to achieve a viral load< 400 copies/ml [US$32; interquartile range (IQR), 20-84 compared with US$22; (IQR, 17-36), P = 0.001]. HAART costs should be minimized as scale-up efforts in sub-Saharan Africa progress.
Referência(s)